Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer

Abstract Mutant KRAS is a key driver in colorectal cancer (CRC) and promotes Myc translation and Myc-dependent stress adaptation and proliferation. Here, we report that the combination of two FDA-approved drugs Bortezomib and Everolimus (RAD001) (BR) is highly efficacious against mutant KRAS CRC cel...

Full description

Bibliographic Details
Main Authors: Hang Ruan, Brian J. Leibowitz, Yingpeng Peng, Lin Shen, Lujia Chen, Charlie Kuang, Robert E. Schoen, Xinghua Lu, Lin Zhang, Jian Yu
Format: Article
Language:English
Published: Springer 2022-03-01
Series:Molecular Biomedicine
Subjects:
Mutant KRAS
Myc
eIF2α
Colorectal cancer
Everolimus
Bortezomib
Online Access:https://doi.org/10.1186/s43556-022-00070-7

Internet

https://doi.org/10.1186/s43556-022-00070-7

Similar Items